Loteprednol

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Summary

Loteprednol is a corticosteroid indicated in the treatment of pain and inflammation after cataract surgery.

Generic Name
Loteprednol
DrugBank Accession Number
DB00873
Background

Not Available

Type
Small Molecule
Groups
Approved, Experimental
Structure
Weight
Average: 394.889
Monoisotopic: 394.154701681
Chemical Formula
C21H27ClO5
Synonyms
  • Loteprednol

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Indication TypeIndicationCombined Product DetailsApproval LevelAge GroupPatient CharacteristicsDose Form
Management ofAcne rosacea••••••••••••••••••••••
Used in combination to treatChickenpoxCombination Product in combination with: Benzalkonium (DB11105)•••••••••••••••••••••• • •••••
Treatment ofCyclitis••••••••••••
Used in combination to treatEye infection viralCombination Product in combination with: Benzalkonium (DB11105)•••••••••••••••••••••• • •••••
Management ofHerpes zoster keratitis••••••••••••
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AcarboseThe risk or severity of hyperglycemia can be increased when Loteprednol is combined with Acarbose.
AcetohexamideThe risk or severity of hyperglycemia can be increased when Loteprednol is combined with Acetohexamide.
AcetyldigitoxinThe risk or severity of adverse effects can be increased when Loteprednol is combined with Acetyldigitoxin.
AlbiglutideThe risk or severity of hyperglycemia can be increased when Loteprednol is combined with Albiglutide.
AlogliptinThe risk or severity of hyperglycemia can be increased when Loteprednol is combined with Alogliptin.
Food Interactions
No interactions found.

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
ALREX STERILE OPHTHALMIC SUSPENSION 0.2%Loteprednol (2 mg/1mL) + Benzalkonium chloride (100 mcg/1mL)Suspension / dropsOphthalmicบริษัท บอช แอนด์ ลอมบ์ (ประเทศไทย) จำกัด2009-02-062020-09-23Thailand flag
LOTEMAX (STERILE OPHTHALMIC SUSPENSION 0.5%)Loteprednol (5 mg/1mL) + Benzalkonium chloride (100 mcg/1mL)Suspension / dropsOphthalmicบริษัท บอช แอนด์ ลอมบ์ (ประเทศไทย) จำกัด2014-02-25Not applicableThailand flag
ZYLET (STERILE OPHTHALMIC SUSPENSION)Loteprednol (5 MG/1ML) + Tobramycin (3.333 MG/1ML)SuspensionOphthalmicบริษัท บอช แอนด์ ลอมบ์ (ประเทศไทย) จำกัด2012-09-25Not applicableThailand flag

Categories

ATC Codes
S01BA14 — Loteprednol
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as androgens and derivatives. These are 3-hydroxylated C19 steroid hormones. They are known to favor the development of masculine characteristics. They also show profound effects on scalp and body hair in humans.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Steroids and steroid derivatives
Sub Class
Androstane steroids
Direct Parent
Androgens and derivatives
Alternative Parents
3-oxo delta-1,4-steroids / 17-hydroxysteroids / 11-beta-hydroxysteroids / Delta-1,4-steroids / Tertiary alcohols / Secondary alcohols / Cyclic ketones / Cyclic alcohols and derivatives / Carboxylic acid esters / Monocarboxylic acids and derivatives
show 4 more
Substituents
11-beta-hydroxysteroid / 11-hydroxysteroid / 17-hydroxysteroid / 3-oxo-delta-1,4-steroid / 3-oxosteroid / Alcohol / Aliphatic homopolycyclic compound / Alkyl chloride / Alkyl halide / Androgen-skeleton
show 18 more
Molecular Framework
Aliphatic homopolycyclic compounds
External Descriptors
organochlorine compound, 11beta-hydroxy steroid, 17alpha-hydroxy steroid, androstanoid, 3-oxo-Delta(1),Delta(4)-steroid, steroid acid ester (CHEBI:50848)
Affected organisms
Not Available

Chemical Identifiers

UNII
Z8CBU6KR16
CAS number
129260-79-3
InChI Key
YPZVAYHNBBHPTO-MXRBDKCISA-N
InChI
InChI=1S/C21H27ClO5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,18(25)27-11-22)20(15,2)10-16(24)17(14)19/h5,7,9,14-17,24,26H,3-4,6,8,10-11H2,1-2H3/t14-,15-,16-,17+,19-,20-,21-/m0/s1
IUPAC Name
chloromethyl (1R,3aS,3bS,9aR,9bS,10S,11aS)-1,10-dihydroxy-9a,11a-dimethyl-7-oxo-1H,2H,3H,3aH,3bH,4H,5H,7H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthrene-1-carboxylate
SMILES
[H][C@@]12CC[C@](O)(C(=O)OCCl)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C

References

General References
  1. Health Canada Approved Drug Products: Lotemax (Loteprednol) Ophthalmic Ointment [Link]
ChemSpider
8041134
RxNav
237027
ChEBI
50848
ZINC
ZINC000030691679
Wikipedia
Loteprednol

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4Unknown StatusTreatmentContact Lens Related Dry Eye1
3WithdrawnTreatmentBacterial Conjunctivitis / Infection Associated Blepharitis / Keratitis / Ocular Inflammation1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Suspension / dropsOphthalmic
Solution / drops5 MG/ML
Solution / dropsOphthalmic5 MG/ML
SuspensionOphthalmic
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0336 mg/mLALOGPS
logP2.2ALOGPS
logP2.52Chemaxon
logS-4.1ALOGPS
pKa (Strongest Acidic)12.01Chemaxon
pKa (Strongest Basic)-2.9Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count4Chemaxon
Hydrogen Donor Count2Chemaxon
Polar Surface Area83.83 Å2Chemaxon
Rotatable Bond Count3Chemaxon
Refractivity102.65 m3·mol-1Chemaxon
Polarizability41.29 Å3Chemaxon
Number of Rings4Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSsplash10-0v7i-1893000000-682774df467cdebbec3b
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-002b-0009000000-a9ad1cd01ce93948bace
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-004l-0009000000-72d728bdb46c9daa479c
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-00ba-1759000000-0cf8387d9ab6e307cf22
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-003r-8009000000-75fc48153255a53258df
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-0bt9-0950000000-2f4b63b0f99fe7cb0450
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-001r-1986000000-c4c109b3f47b57fa65c9
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-197.1373621
predicted
DarkChem Lite v0.1.0
[M-H]-188.75484
predicted
DeepCCS 1.0 (2019)
[M+H]+197.7193621
predicted
DarkChem Lite v0.1.0
[M+H]+190.65027
predicted
DeepCCS 1.0 (2019)
[M+Na]+197.3368621
predicted
DarkChem Lite v0.1.0
[M+Na]+197.2534
predicted
DeepCCS 1.0 (2019)

Drug created at August 24, 2018 15:59 / Updated at March 18, 2024 19:36